Arvinas Inc (ARVN)
26.80
-1.07
(-3.84%)
USD |
NASDAQ |
Mar 30, 16:00
26.80
0.00 (0.00%)
After-Hours: 20:00
Key Stats
| Price and Performance | |
|---|---|
| Market Cap | 1.428B |
| 52 Week High (Daily) | Upgrade |
| 52 Week Low (Daily) | Upgrade |
| All-Time High (Daily) | Upgrade |
| Year to Date Total Returns (Daily) | Upgrade |
| 1 Month Total Returns (Daily) | Upgrade |
| 1 Year Total Returns (Daily) | -58.76% |
| Valuation | |
| PE Ratio | -- |
| PE Ratio (Forward) | Upgrade |
| PS Ratio | 10.86 |
| Price to Book Value | 2.527 |
| EV to EBITDA | Upgrade |
| Dividend | |
|---|---|
| Dividend | -- |
| Dividend Yield (Forward) | Upgrade |
| Financials | |
| Revenue (5 Year Growth) | Upgrade |
| Revenue (Quarterly YoY Growth) | Upgrade |
| EPS Diluted (5 Year Growth) | Upgrade |
| EPS Diluted (Quarterly YoY Growth) | Upgrade |
| Debt to Equity Ratio | 0.0018 |
| Return on Equity | Upgrade |
| Return on Assets | Upgrade |
| Risk | |
| Beta (5Y) | Upgrade |
| Max Drawdown (5Y) | -- |
News
Headline
Wire
Time (ET)
MT Newswires
02/27 10:20
MT Newswires
02/24 09:31
MT Newswires
02/23 10:16
Events
| DATE | TIME | TYPE | PERIOD | REPORTED EPS |
ESTIMATED EPS |
SURPRISE | |
| 05/05/2023* | -- | Results | Q1 2023 | -- | -- | -- | |
| 02/23/2023 | -- | Results | Q4 2022 | -1.56 | -1.10 | -41.24% | |
| 11/09/2022 | -- | Results | Q3 2022 | -1.24 | -1.07 | -15.62% | |
| 08/04/2022 | -- | Results | Q2 2022 | -1.32 | -1.04 | -27.12% | |
| 05/05/2022 | -- | Results | Q1 2022 | -1.20 | -0.91 | -32.19% | |
| 02/28/2022 | -- | Results | Q4 2021 | -1.00 | -0.74 | -34.97% | |
| 11/03/2021 | -- | Results | Q3 2021 | -0.94 | 2.13 | -144.2% | |
| 08/05/2021 | -- | Results | Q2 2021 | -1.03 | -0.86 | -19.54% |
*Estimated Date/Time
Earnings
Profile
| Arvinas Inc is a United States-based biopharmaceutical company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development and commercialization of therapies that degrade disease-causing proteins.. The company's proprietary Proteolysis-Targeting Chimera (PROTAC), work by inducing the cell's own ubiquitin-proteasome system to target, degrade and remove disease-causing proteins. The group's product candidates are bavdegalutamide, ARV-471 and ARV-766. |
| URL | https://www.arvinas.com |
| Investor Relations URL | https://ir.arvinas.com/ |
| HQ State/Province | Connecticut |
| Sector | Healthcare |
| Industry | Biotechnology |
| Equity Style | Small Cap/Growth |
| Next Earnings Release | May. 05, 2023 (est.) |
| Last Earnings Release | Feb. 23, 2023 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |
Analyst Coverage
|
Consensus Rating
|
|
|
Analyst Recommendation
|
|
Source: S&P Global
Dividends
| Dividend Per Share (TTM) | -- |
|
2017
2018
2019
2020
2021
6.00%
4.00%
2.00%
|
|
| Yield to Market | 0.00 |
| Yield to Sector | 0.00 |
| Yield to Industry | 0.00 |
| Last Dividend Amt. | -- |
| Dividend Frequency | -- |
| Last Ex-Dividend Date | -- |
| Yield (TTM) | 0% |
| Forward Yield | -- |
| Payout Ratio | 0.00% |
| Cash Payout Ratio | 0.00% |
| Consistent Payer (5Y) | No |
| Consistent Growth (5Y) | No |
Risk
Total Returns Comparison
Annual Total Returns Versus Peers
As of March 29, 2023.
Fundamentals
| Revenue (TTM) | 131.40M |
| Total Expenses (TTM) | 394.70M |
| Net Income (TTM) | -282.50M |
| Total Assets (Quarterly) | 1.269B |
| Total Liabilities (Quarterly) | 703.90M |
| Shareholders Equity (Quarterly) | 564.90M |
| Cash from Operations (TTM) | -273.50M |
| Cash from Investing (TTM) | 242.80M |
| Cash from Financing (TTM) | 4.70M |
Ratings
Profile
| Arvinas Inc is a United States-based biopharmaceutical company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development and commercialization of therapies that degrade disease-causing proteins.. The company's proprietary Proteolysis-Targeting Chimera (PROTAC), work by inducing the cell's own ubiquitin-proteasome system to target, degrade and remove disease-causing proteins. The group's product candidates are bavdegalutamide, ARV-471 and ARV-766. |
| URL | https://www.arvinas.com |
| Investor Relations URL | https://ir.arvinas.com/ |
| HQ State/Province | Connecticut |
| Sector | Healthcare |
| Industry | Biotechnology |
| Equity Style | Small Cap/Growth |
| Next Earnings Release | May. 05, 2023 (est.) |
| Last Earnings Release | Feb. 23, 2023 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |
Ownership
| Insider Ownership Percentage | Upgrade |
Jul '20
Nov '20
Mar '21
80.00%
40.00%
10.00%
Analyst Coverage
|
Consensus Rating
|
|
|
Analyst Recommendation
|
|
Source: S&P Global
Top Fund Holders
| Symbol | Dollars Invested | % Weight |
|---|---|---|
| F00001EX33 | 337316.0 USD | 3.37% |
| XPH | 2.923M USD | 1.53% |
| PHPSX | 27589.00 USD | 0.66% |
Other Resources
| Whale Wisdom | 13F Filings |
| Seeking Alpha | Call Transcripts |
| Nasdaq | Insider Trading |
| Nasdaq | Institutional Ownership |
| Nasdaq | Option Chain |
| SEC | SEC Filings |
| ARVN Tweets |